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Heat shock proteinAbstract Non-communicable diseases such as cancer, atherosclerosis and diabetes are responsible for
major social and health burden as millions of people are dying every year. Out of which, atherosclerosis
is the leading cause of deaths worldwide. The lipid abnormality is one of themajormodiﬁable risk factors
for atherosclerosis. Both genetic and environmental components are associated with the development of
atherosclerotic plaques. Immune and inﬂammatory mediators have a complex role in the initiation and
progression of atherosclerosis. Understanding of all these processes will help to invent a range of new bio-
markers and novel treatment modalities targeting various cellular events in acute and chronic inﬂamma-
tion that are accountable for atherosclerosis. Several biochemical pathways, receptors and enzymes are
involved in the development of atherosclerosis that would be possible targets for improving strategies
for disease diagnosis and management. Earlier anti-inﬂammatory or lipid-lowering treatments could be
useful for alleviating morbidity and mortality of atherosclerotic cardiovascular diseases. However, novel
drug targets like endoglin receptor, PPARa, squalene synthase, thyroid hormone analogues, scavenger
receptor and thyroid hormone analogues are more powerful to control the process of atherosclerosis.
Therefore, the review brieﬂy focuses on different novel targets that act at the starting stage of the plaque
form to the thrombus formation in the atherosclerosis.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
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coronary arteries.1. Introduction
Cancer, diabetes, obesity, myocardial infarction, hyperlipid-
emia, chronic respiratory diseases and cardiovascular disease
(CVD) like atherosclerosis are the major non-communicable
diseases (NCD). These NCD are the leading causes of death
worldwide in not only high-income population but in the mid-
dle and low group (Margaret, 2010). Atherosclerosis is the
chronic inﬂammatory disease which overall increases the mor-
bidity and the mortality rate (John, 2000).The development of
the level of atherosclerosis from an early fatty streak lesion to a
highly hazardous rupture-prone plaque is because of the many
cellular and molecular events at each level hence, it is the
inﬂammatory event (Robert, 2005). These fatty streaks are
one of the signs of atherosclerosis, which is ﬁrst observed by
Russell Holman and this fatty streak develops, thrombosis
or hemorrhage (Brian et al., 2012).
A persistent increase in circulating low-density lipoprotein
(LDL) levels in the body is one of the most important causes
for the initiation and progression of atherosclerosis. In this re-
spect, macrophages play a very important role by increasing
accumulation of lipids in blood vessels, leading to inﬂamma-
tion and plaque formation. There are two different theories
proposed to describe the events involved in atherogenesis.
The ﬁrst hypothesis is ‘‘response to injury,’’ in which endothe-
lial lining’s injury initiates events of deposition of LDL in theintimal space, followed by recruitments and migration of
monocyte-derived macrophages, which take up modiﬁed
LDL and become foam cells (John, 2000; Ross, 1993; Ross
et al., 1977). The second hypothesis is ‘‘response to retention’’;
LDL is deposited in the intimal space and undergoes modiﬁca-
tion. Modiﬁed LDL serves as a chemoattractant for mono-
cytes and macrophages. Macrophages remove modiﬁed LDL
via scavenger receptors and become foamy (Williams and Ta-
bas, 1995). In brief, LDL accumulates within the intimal space
and subsequently undergoes modiﬁcation such as oxidation,
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immunogen (Wilensky and Hamamdzic, 2007). Oxidation of
LDL in the intimal space is still not known exactly; however,
lipoxygenases, myeloperoxidase, inducible nitric oxide syn-
thase and NADPH oxidases have LDL oxidation capacity
(Li and Glass, 2002).The activated endothelial cells (EC) en-
hance the expression of adhesion molecules, such as intracellu-
lar adhesion molecule, vascular cell adhesion molecule, E- and
P-selectin. Adhesion molecules have a major role in monocyte
recruitment on the arterial endothelium. P-selectin binds to P-
selectin glycoprotein ligand-1, which is present on monocytes
(John, 2005; Elstad et al., 1995). P-selectin glycoprotein li-
gand-1 allows the capturing, rolling and activation of mono-
cytes (Weyrich et al., 1995). P and E-selectin has similar
functions in atherosclerosis progression (Chandak et al.,
2011). VCAM-1 is another important molecule in monocyte
recruitment and ﬁrm adhesion to the endothelial surface. Very
late antigen-4 expressed by monocytes is a ligand for vascular
cell adhesion molecule -1. Intracellular adhesion molecule has
a role in monocyte adhesion, spreading and migration into the
sub-endothelial space (Chandak et al., 2011). Monocytes enter
the endothelial space and differentiate into macrophages by
macrophage colony-stimulating factor secreted by EC and
smooth muscle cells (SMCs). Activated macrophages in the
sub-endothelial space secrete macrophage-chemoattractant
protein-1. EC induces the expression of macrophage-chemoat-
tractant protein-1 in the presence of oxidized phospholipids,
which are components of oxidized LDL (Li and Glass,
2002). Macrophages remove modiﬁed LDL via scavenger
receptor A, scavenger receptor B1 and cluster of differentiation
36. After internalization, endosomes are transferring LDL to
lysosomes. After lysosomal degradation of LDL, free choles-
terol is produced, which is re-esteriﬁed into cholesteryl esters
via acyl-CoA: cholesterol acyltransferase1 (ACAT1). Accumu-
lation of lipid-laden macrophages (foam cells) in the arterial
wall is the hallmark of atherosclerosis. The atherosclerosis is
the major complication of diabetes mellitus because many
studies found that the diabetic patients have 2–5 times the
death rate than non-diabetic patients (Gerrity and Antonoy,
1997). Atherosclerosis progression is characterized by develop-
ment of plaque on the insides of arteries, which later hardens
and narrows the arteries, leads to reduced supply of oxygen-
rich blood to organs and other parts of the body. This can lead
to various serious cardiovascular complications like heart at-
tack, stroke, or even death (Paolo et al., 1995). Fig. 1 shows
the development of atherosclerotic-plaque in the coronary ar-
tery. Management of adverse cardiovascular outcomes of ath-
erosclerosis through risk factor identiﬁcation and modiﬁcation
has been an active area of research over the past few decades.
As a result, several large scale randomized clinical trials and
observational studies have shown intensive risk reduction ther-
apy to be very effective and critical in reducing adverse cardio-
vascular outcomes in patients with atherosclerosis (Mervi
et al., 2012).2. Epidemiology
In 1997, the latest year for which statistics are available, CVD
claimed 953,110 lives in the United States presenting 41% of
all deaths. CVD is the foremost source of morbidity and mor-
tality in the western world. The risk of cardiovascular diseasesis wicked because these diseases are derived per year than the
later seven primary cause of death combined. Under the age of
65–70 approximately 1/6 population was killed by CVD of
which 30% were men and 24% were women and 41% were
men, and 40% were women in the black population. The
World Health Organization predicts that continued global eco-
nomic prosperity will likely lead to an epidemic of cardiovas-
cular disease as developing countries are continuously
acquiring Western habits which are the principal problem over
the world. Hence, CVD is the major health problem that will
only have wider effects over the resultant decades (John, 2000).
The class of cardiovascular diseases mainly includes NCD
and is the cause of 57 million global deaths in 2008, 36 million
or 63% happened, and predominantly NCD includes, athero-
sclerosis, diabetes, cancers and chronic respiratory diseases
(Anthony, 2005). Low and middle-income regions show nearly
80% of the burden of diseases like cardiovascular disease, can-
cer, diabetes and chronic respiratory diseases (Margaret,
2010). Hypertension is one of the few recognized determinants
of atherosclerosis. Various expressions of the atherosclerotic
vascular disease are a leading cause of death and disability in
industrialized countries. Arterial hypertension is found in
65 million Americans and over 1 billion individuals worldwide
(John, 2005). Based on epidemiological studies of atherosclero-
sis using autopsy material in ﬁve European cities, which were
carried out with an interval of 25 years in the 1960s and 1980s,
respectively, it is revealed that atherosclerosis in young so-called
practically healthy people, 20–39 years of age, who died from
accidental causes, closely reﬂects the level of atherosclerosis in
the population as a whole (Valentin and Nils, 2004).
Recently, China reports that the more effect of LDL and tri-
glycerides (TG) shows age related speciﬁc value. The major risk
of atherosclerosis increased 16–36% from 1950 to 1987 due to
the increased dietary fat in Taiwan (Wen-Harn and Benjam,
1995).The self- regulating risk factor for atherosclerosis is hype-
rhomocysteinemia. It is found that the updated epidemic impact
of cardiovascular disease in India is very high that is the inci-
dence rate is almost 80–120 per 1000 populations. European
population shows more levels of homocysteine as compared to
Asian Indians which was believed to cause twice as many coro-
nary heart disease (CHD) deaths. This indicates that homocys-
teine was an independent risk factor in Asian Indians, which
probably contributed to the increased CHD risk (Sainani
et al., 2008). In 1990–1991Chin-ShanCommunityCardiovascu-
larCohort (CCCC) study reported that the postmenopausal wo-
men showed higher atherogenic lipids than in premenopausal
women. The postmenopausal increases were particularly signif-
icant in total cholesterol (TC) and low density lipoprotein cho-
lesterol (LDL-C) among women aged 45–49 years, and in TG
and Apo B among women aged 50–54 years (Pao-Ling et al.,
2002).
Each year in Australia approximately 48,000 ‘major coro-
nary events’ occur, equivalent to about 130 events per day of
these events, about 40% are fatal. With medical advances
worldwide, the number of people surviving an acute cardiac
event and therefore, living with established CHD, has been
greater than before (Barbara et al., 2011).The primary mortal-
ity and the disability are adjusted in Europe and are raised in
developing countries due to atherosclerosis of the arterial ves-
sel wall and to thrombosis formation. Indirect and direct
healthcare cost in the European Union, the economic cost of
CVD represents annually 192 billion. In the United States, it
182 P.G. Jamkhande et al.is established as 5.4 million, individuals have been diagnosed
with diabetes and around 2.4 million are without diagnosis.
Death rates among adults, atherosclerosis with diabetes are
2–4 times higher than for those without diabetes. It is observed
that approximately 14,000,000 people in the United States
have atherosclerotic coronary disease as a major complication
of diabetes mellitus (John, 2000; Jonathan et al., 2012).3. Risk factors
The aspect of the risk related to a speciﬁc disease in a behavior
that is sturdily and constantly associated with that disease is de-
ﬁned as a risk factor. Atherogenesis is a multifactorial and com-
plex progressionwhichmakes it difﬁcult to clearly deﬁne the risk
attributable to any one risk factor process. For clear under-
standing of a risk factor, a trait must be causally linked to a par-
ticular disease in a manner that is strongly and consistently
associated with that disease. Obesity is clearly associated with
an increased risk of atherosclerosis; however, this association
seems to be mediated in large part by abnormalities in diabetes,
hypertension, and lipoproteins which are all known risk factors
for atherosclerosis (Sandra and Frank, 2011).The purpose of
discussion is to focus on established risk factors and their contri-
bution in the development of atherosclerosis.
3.1. Cigarette smoking
The relation of the cigarette smoking and heart disease was ob-
served from 1940s which shows the relationship between smok-
ing and heart diseases. Surgeon General update report showed
that smoking increases atherosclerotic disease by more than
50% and doubles the incidence of coronary heart disease (John,
2000). Smoking increases arterial wall stiffness (resulting in re-
duced distensibility and compliance), increases ﬁbrinogen levels,
increases platelet aggregation, decreases high-density lipopro-
tein cholesterol levels, and increases hematocrit (John, 2000;
Sarah andBruce, 2009;David, 2007). Smoking causes an inﬂam-
matory state with high concentrations of C-reactive protein and
ﬁbrinogen, and it has long been recognized as a risk factor for
cardiovascular disease (John, 2000). Genetic factors may inﬂu-
ence whether smokers develop carotid, coronary and peripheral
vascular atherosclerosis. Different genetic variants of the parao-
xonase-1, which codes for an enzyme with antioxidant proper-
ties, are associated with greater risk for atherosclerosis in
smokers than in nonsmokers (Bradford and Thomas, 2002).
Exposure to cigarette smoke signiﬁcantly up-regulates EPHX2
gene and protein expression in the vasculature, suggesting a pos-
sible role of this gene for its deleterious effects (Qi et al., 2007).
The cessation of smoking declines stroke risk associated with
former smoking to almost that of risk level of nonsmokers at
2–5 years from cessation (John, 2000; Sarah and Bruce, 2009;
Bradford and Thomas, 2002; Steve and Laleh, 2004).3.2. Hypertension
Atherosclerosis is one of the major contributing factors which
may inﬂuence the course of the atherosclerosis (Sarah and
Bruce, 2009; Steve and Laleh, 2004). Hypertension and athero-
sclerosis are intimately linked by the EC which forms at the
interior surface of the vascular system. This lumen-vascularwall boundary function as a semi permeable membrane, main-
tains nonthrombogenic blood-tissue interface (by regulating
thrombosis, thrombolysis, and platelet adherence), modulates
vascular tone and blood ﬂow, and metabolizes hormones. Also
it regulates immune and inﬂammatory reactions, modify lipo-
proteins in the arterial wall, and regulate the growth of other
cell types, particularly smooth muscle cell reactions. Shearing
forces associated with wide arterial pulse pressures serve to
activate the endothelium to induce genetic expression like
procoagulant, inﬂammatory, and other responses that ulti-
mately prove harmful to the endothelium and vessel wall.
Chronic and repetitive endothelial injury promotes intimal
thickening and a shift from the contractile phenotype to the
proliferative-synthetic phenotype. Alteration of shear stress
during hypertension, such as elevated pulse pressures, and
stimuli from additional risk factors combine to increase endo-
thelial permeability. Lipids accumulate within the intima at
sites of increased endothelial permeability and endure various
changes like oxidative modiﬁcation of LDL by free radicals,
formation of foam cells, increased monocyte adhesion.
Oxidized LDL further stimulates the release of growth factors
and cytokines, which is cytotoxic to EC and smooth muscle
cells, and is immunogenic, inducing antibodies to oxidized
lipoproteins. These events cumulate in thin-walled atheroscle-
rotic plaques containing foam cells and activated macro-
phages. The hemodynamic shearing force of hypertension
ruptures the vulnerable plaque. A ruptured plaque leads to
atherothrombosis, occlusion of the lumen (John, 2005).
3.3. Diabetes mellitus
Type 2 diabetes patients are frequently prone to atheroscle-
rotic complications, which account for more than 80% of all
diabetic mortality (Sainani et al., 2008). Dyslipidemia charac-
terized by elevated small dense LDL levels, lowered high den-
sity lipoproteins (HDL) levels, and elevated TG levels is
associated with coronary heart diseases (Sarah and Bruce,
2009). Type 2 diabetes also promotes formation of coronary
calciﬁcation, which is a potential marker for subclinical ath-
erosclerosis (Bradford and Thomas, 2002). Thus, diabetes rep-
resents a major causative risk factor to atherosclerosis in the
developed world (Anthony et al., 2005).
3.4. Serum cholesterol
The relation between cholesterol and atherosclerosis is explicit
naturally. Elevated serum cholesterol levels are associated with
higher atherosclerotic stroke risk (Sarah and Bruce, 2009).
Cholesterol is an essential compound for the synthesis of bile
acid, many hormones such as testosterone, estrogen, dihydro-
epiandrosterone, progesterone, cortisol and required to pro-
duce vitamin D. Plaques are formed by LDL cholesterol and
oxidized LDL deposits in arterial walls, which later grows
and rupture, leading to artery-blocking by formation of small
blood clots (Anthony, 2005). It has been identiﬁed that multi-
ple loci, polymorphisms of the paraoxonase-1, mutations of
the endothelial constitutive nitric oxide synthase inﬂuence ser-
um LDL cholesterol level (Bradford and Thomas, 2002).
The hypercholesterolemia is a disorder which affects approx-
imately one in 500 persons from the general population. Hetero-
zygote hypercholesterolemia disorder contains apparently
Figure 2 Shows endothelial injury progression for atherosclerosis initiation model. Several risk factors, such as hypertension, elevated
oxidized low density lipoprotein level, hyperglycemia, cigarette smoking, and homocysteine promote atherogenesis through upregulation
of genes and activation of macrophages and T-lymphocytes and increase lipid deposition. The top of the ﬁgure represents the intraluminal
space, and the bottom represents the subendothelial matrix, and SMC.
Therapeutic approaches to drug targets in atherosclerosis 1832–3-fold elevated plasma cholesterol whereas homozygotes have
4 ± 6-fold elevation in plasma cholesterol due to functional
defects in the LDL receptor that interfere with LDL clearance.
This leads to myocardial infarction by the age of 60 in heterozy-
gotes and this age is reduced to 15 in patients who are homozy-
gous (John, 2000).
Fig. 2 outlines the contribution of several etiological factors
such as hypertension, elevated oxidized low density lipoprotein
level, hyperglycemia, cigarette smoking, and homocysteine in
the endothelial injury which further leads to initiation of athero-
sclerosis because of upregulation of genes and activation ofmac-
rophages andT-lymphocytes and increases lipid deposition. The
reduced lumen diameter is the outcome of events occurred in
intraluminal space, subendothelial matrix and smooth muscle
cells during the progress of atherosclerotic-plaque.
3.5. Newer risk factors
Homocysteine is a highly reactive amino acid exhibiting toxic-
ity for vascular endothelium and enhances auto-oxidation of
LDL. Hyperhomocysteinemia is a potential risk factor foratherosclerosis, which interacts with other vascular risk factors
and has demonstrable genetic and dietary determinants. Poly-
morphisms of 5,10-methylene tetrahydrofolate reductase is
associated with atherosclerosis (Steve and Laleh, 2004). Aug-
mented serum uric acid (SUA) (Markus et al., 2012) has been
associated with coronary artery diseases (CAD), coronary cal-
ciﬁcation, carotid atherosclerotic plaques, increased carotid in-
tima-media thickness, arterial stiffness and with the metabolic
syndrome (Mervi et al., 2012). Modiﬁed malondialdehyde and
oxidized LDL have been playing an increasing role in athero-
sclerotic lesions. Elevated titers of autoimmune antibodies spe-
ciﬁc for malondialdehyde (MDA)-modiﬁed LDL predicted the
progression of carotid atherosclerosis (Paul and Desire, 1998).
Patients with urinary stone disease should be at higher risk for
other vascular complications and atherosclerosis is one of
them (Alexander et al., 2011). Genetic risk factors related to
the angiotensin converting enzyme (ACE), are also identiﬁed
as increasing the risk of atherosclerosis (Pieter et al., 2001).
Porphyromonas gingivalis, a major periodonto-pathogen, is
associated with progression of atherosclerosis. P. gingivalis
can accelerate atheroma deposition by inﬂammatory response,
Figure 3 Shows the role of soluble endoglin in atherosclerosis: cardiovascular diseases like atherosclerosis, hypertension, diabetes
mellitus and preeclampsia, increase levels of soluble endoglin in blood in humans that leads to increased interactions between endoglin and
TGFb1 in blood followed by reduced TGF-b signaling in vessels, thus promoting atherogenesis. Statins, reduction of cholesterol levels and
application of extracorporeal procedures decrease soluble endoglin levels in blood, which may result in an increased TGFb1 signaling in
the vessel wall and possibly affect atherogenesis (Petr et al., 2012).
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and/or chemokines that ultimately modulate early atherogene-
sis that spontaneously develop atherosclerosis. Pathogens can
upregulate the expression of innate immune receptors on the
surfaces of both endothelial cells and macrophages (Qian
et al., 2009). The recent update found that the intracellular bac-
terial pathogen Chlamydia pneumoniae causes respiratory tract
infection and has been associated with atherosclerosis and cor-
onary artery disease. C. pneumoniae is involved in all stages
of atherosclerosis including initiation, inﬂammation, ﬁbrous
plaque formation, plaque rupture and thrombosis (James and
Brian, 2001). Low level of ascorbic acid is a major risk factor
and indicator of atherosclerotic CVD, including hypertension
and elevated concentrations of LDL, acute phase proteins,
and hemostatic factors (Sagar et al., 2012). Increased platelet ac-
tion in the body can increase the atherosclerosis risk and plaque
calciﬁcation also increases the risk of atherosclerosis (Amala
et al., 2012). Leptinmay contribute to the development of classic
risk factors of atherosclerosis such as arterial hypertension and
diabetes mellitus (Jerzy, 2006).
4. New drug targets of atherosclerosis
4.1. Activators of peroxisome proliferator-activated receptor
Peroxisome proliferator-activated receptor (PPARs) agonists
are considered as a therapeutic target for diabetes, dyslipide-
mia, and atherosclerosis because they are the members of the
nuclear receptor major family that characterizes as fatty
acid-activated transcription factors; they are the regulator of
numerous metabolic pathways. Three different PPAR genes
(a, b/d, and c) have been identiﬁed. Kidney, liver, skeletal
and cardiac muscle, and adrenal gland tissue include in lipid
oxidation mainly characterized by the PPARa. Activated
PPARa increases expression of lipoprotein lipase and apolipo-
protein A-V and decreases hepatic apolipoprotein C-III. These
actions lower plasma TGs in chylomicrons and very low den-
sity lipoprotein (VLDL) particles, thus liberating fatty acids
(FAs), which are taken up and stored as fat in adipocytes or
metabolized in skeletal muscle. Also PPARa activation in-
creases hepatic apolipoprotein A -I and –II expressions, whichraise HDL cholesterol levels, and promote HDL-mediated
cholesterol efﬂux from macrophages by inducing ATP-binding
cassette A1 transporter. PPARa is also associated with regula-
tion of genes involved in FAs uptake, b-oxidation and down-
regulates a protein apolipoprotein C-III that inhibits TG
hydrolysis by lipoprotein lipase, and it also interferes with
genes involved in reverse cholesterol transport like apolipopro-
tein A-I and A-II. PPARc is present in adipose tissue, macro-
phages, and vascular smooth muscles, while PPARc is mainly
expressed in skeletal muscle and adipose tissues. PPAR b/d is
involved in skin homeostasis, and is involved in HDL metab-
olism. Use of PPARa and PPARc agonists may be effective in
the management of atherosclerosis (Sagar et al., 2012; Kristina
et al., 1996).
4.2. Endoglin receptor
Endoglin (CD 105, TGF-b receptor III) is a homodimeric
transmembrane glycoprotein having a regulatory role in trans-
forming growth factor – b (TGF-b) signaling, predominantly
expressed on proliferating endothelial cells. This protein is
characterized as homodimer of 180 kDA with disulﬁde attach-
ment. It is primarily observed in endothelial cells, smooth mus-
cle cells, activated macrophages, and ﬁbroblast. Expression of
endoglin in vessels increases during different pathological situ-
ations including hypoxia or vascular injury. Phosphorylation
of endoglin can impede its subcellular localization and cellular
migration. In general, endoglin expression is strongly related
to cardiovascular system development, vascular development,
angiogenesis and vascular homeostasis. Endothelial cells play
an important role in the pathogenesis of atherosclerosis. Endo-
thelial dysfunction, characterized by increased expression of
inﬂammatory cell adhesion molecules, altered vasodilation
properties and a prothrombogenic state, is very signiﬁcant in
every stage of atherogenesis. SMCs play the essential role in
the development of atherosclerotic lesions due to the increment
in the extracellular matrix and also for the stabilization of the
difﬁcult atherosclerotic plaques because of the ﬁbrous cap
which is produced by the collagen formation. Fig. 3 shows
involvement of endoglin in the development of atherosclerosis
and associated cardiovascular diseases. Endoglin expression is
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tion, and the regulation of the function of endothelial cells.
Hence, endoglin is necessary for the vascular SMC stability
as well as its development by inhibition of SMC migration
due to the regulation of TGF-b (Petr et al., 2012, 2008; Fran-
cisco and Carmelo, 2012). Reduction of cholesterol level by
drugs like statin involves endoglin mediated action.4.3. Cholesteryl ester transfer protein inhibitors
Cholesterol ester transfer protein (CETP) is a lipid transfer
protein that facilitates the transport of cholesterol ester and
TG within the lipoproteins in the blood to mediate the way
of transfer of cholesterol ester from the HDL to the LDL
and VLDL which should be proatherogenic (Philip and John,
2006). Thus, the movement of cholesteryl esters from HDL to
LDL by CETP leads to lowering of HDL. It therefore, follows
that inhibition of CETP should lead to elevation of plasma
HDL and lowering of plasma LDL, thereby providing a ther-
apeutically beneﬁcial plasma lipid proﬁle. Inhibition of CETP
is a choice of treatment in the lipid proﬁle related disorders like
atherosclerosis and type II diabetes (Sagar et al., 2012; John
et al., 2010).
4.4. Cholesterol absorption inhibitors
Decrease in cholesterol absorption leads to compensatory up-
regulation of LDL receptors on the cell surface and increased
LDL cholesterol uptake into cells and decreases blood LDL
cholesterol content (Sagar et al., 2012; John et al., 2010). Eze-
timibe is the only drug of this class having the ability to inhibit
absorption of dietary cholesterol without affecting the absorp-
tion of fat-soluble vitamins, triglycerides, and bile. Ezetimibe
binds to cholesterol transporter Niemann-pick C1-like1 pro-
tein in the brush border of the intestine as well as in hepato-
cytes thereby inhibiting absorption of cholesterol (Sagar
et al., 2012; Stuart et al., 1998).4.5. Cholesterol O-acyltransferase inhibitors
Acyl-CoA: cholesterol O-acyltransferase (ACAT) is a chief en-
zyme involved in re-esteriﬁcation of absorbed cholesterol within
enterocytes. ACAT has a role in cholesterol metabolism inmac-
rophages, liver, intestine and adrenal cortex and is believed to be
involved in secretion ofVLDL from liver and development of an
atherosclerotic lesion. There are two types of ACAT enzymes,
ACAT1 and ACAT2. ACAT1 is present in the ER throughout
the body, while ACAT2 found in the ER of liver and intestinal
tissues and may be responsible for the formation of cholesteryl
esters. Inhibition of ACAT1 may prevent the transformation
of macrophages into foam cells in the vessel wall and, thereby,
reduce the progression of atherosclerosis and prevent the devel-
opment of vulnerable plaque whereas inhibition of ACAT-2
leads to a decrease in serum lipid levels by reducing the synthesis
of lipoproteins (Sagar et al., 2012).
4.6. Diacylglycerolacyltransferases inhibitors
Diacylglycerolacyltransferase (DGAT) is an integral mem-
brane protein that catalyzes the ﬁnal enzymatic step in theproduction of triacylglycerols by transferring an acyl group
from acyl-coenzyme-A to the sn-3 position of 1,2-diacylglyc-
erol (Kathryn et al., 2001). It also plays a role in accumulation
of lipid adipocyte (Sagar et al., 2012). DGAT is also involved
in lipoprotein assembly and the regulation of plasma triacyl-
glycerol concentration, as well as participates in the regulation
of DAG levels (Kathryn et al., 2001). DGAT1 belongs to the
same family of proteins as the ACATs and is present in skeletal
muscle skin, intestine (ileum, colon), and testis, with lower lev-
els of expression in the liver and adipose tissue, while DGAT2
is ubiquitous with high expression levels in hepatocytes and
adipocytes (Sagar et al., 2012). DGAT-1 knockout mice were
protected from atherosclerosis development (Chandak et al.,
2011). Inhibition of DGAT may reduce the risk associated
with atherosclerosis.4.7. Microsomal TG transfer protein inhibitors
Microsomal TG transfer protein (MTTP) is a heterodimeric li-
pid transfer protein present in the intestine and liver tissues
where it is involved in lipid assembly, transport, and secretion
of lipoproteins, TG rich chylomicrons (in enterocytes), and
VLDL (in hepatocytes). It also plays a role in transportation
of TG, cholesteryl ester, and phosphatidylcholine between
the membranes. In vitro studies show that MTTP catalyzes
the transport of molecules between phospholipid membranes
and is also involved in the synthesis of nascent lipoprotein par-
ticles within the lumen and ER (Sagar et al., 2012). Defects in
MTTP cause a beta-lipoproteinemia, a disorder characterized
by production of VLDL and chylomicrons is disrupted (John
et al., 1998). The inhibition of MTTP causes reduction in plas-
ma TGs and cholesterol levels which thereby reduces the risk
of atherosclerosis.
4.8. Squalene synthase inhibitors
Squalene synthase, a key enzyme in the cholesterol biosyn-
thetic pathway, occupies the ﬁrst and solely committed step
in the biosynthesis of the sterol nucleus of cholesterol; hence
it is an attractive target to manage elevated serum cholesterol
and thereby for atherosclerosis. Squalene synthase catalyzes
one of the subsequent reactions in the cholesterol biosynthetic
pathway. It reductively dimerizes two farnesyl pyrophosphate
molecules to form squalene which is the ﬁrst intermediate com-
mitted to cholesterol (Sagar et al., 2012). It has been shown
that squalene synthase inhibitor suppresses triglyceride biosyn-
thesis in hepatocytes but the mechanism is not precisely known
(Tohru et al., 2002).
4.9. Thyroid hormone analogues
Thyroid hormone has potential to reduce total serum choles-
terol by accelerating LDL clearance rate in hyperthyroidism
like conditions (Sagar et al., 2012).This unique property of
lowering cholesterol improves cardiac performance (Eugene
et al., 2004). It has been suggested that hypercholesterolemia,
hypertension and impaired endothelial function in the hypo-
thyroid state augment atherogenesis (Francoise et al., 2009).
In addition, recent studies suggest that hypothyroidism is asso-
ciated with the emerging risk factors for atherosclerosis such as
Table 1 Drug targets and its mechanism of action for atherosclerosis.
Drug targets Mechanism of action References
PPARc selective
modulator
Decreases insulin resistance Kristina et al. (1996)
Anti-inﬂammatory eﬀects in macrophage foam
cells
Sagar et al. (2012)
Endoglin receptor
modulator
Reduces expression of inﬂammatory cell
adhesion molecules
Francisco and Carmelo (2012)
Increases vascular smooth muscle cell Petr et al. (2012, 2008)
Stabilize and reduce prothrombogenic state
CETP inhibitor Increases HDL cholesterol levels John et al. (2010), Philip and John
(2006), Sagar et al. (2012)
Reverses cholesterol transport system
ACAT enzyme
inhibitor
Prevents transformation of macrophages into
foam cells
Sagar et al. (2012)
Decreases synthesis of lipoproteins
PPARa agonist Decreases TG-rich lipoproteins Kathryn and Mason (2006)
Increases HDL Kristina et al. (1996), Philip and
John (2006), Sagar et al. (2012)
Anti-inﬂammatory eﬀects in vessel wall
DGAT enzyme
inhibitor
Inhibit transfer of acyl group from acyl-
coenzyme-A to the sn-3 position of 1,2-
diacylglycerol





Prevents lipid assembly, transport, secretion of
lipoproteins, triglyceride rich chylomicrons (in
enterocytes) and VLDL
Eugene et al. (2004), Jeﬀrey et al.
(2001) Sagar et al. (2012)




Prevent biosynthesis of the sterol nucleus of
cholesterol




Increases activity of lipoprotein lipase Eugene et al. (2004), Paul and





Restrain four-ringed sterol intermediate
formation
Andrea et al. (2003), Sagar et al.
(2012)




Regulate conversion of cholesterol to 7a-
hydroxycholesterol
Irina (2006)
Sagar et al. (2012)
AMPK activator Regulates glucose metabolism Bei et al. (2009), Sagar et al.
(2012)
Decreases hepatic lipogenesis, synthesis of new
FA and cholesterol
Increases FA oxidation
Omega-3 FAs Inhibit expression of SREBP-1 Sagar et al. (2012), Vasilios et al.
(2011)




Reduction in immune tolerance against self
antigen
Long et al. (2012)
Prevent transfer of CE into triglyceride-rich
lipoproteins or LDL
sPLA2 inhibitor Prevents inﬂammatory, autoimmune and allergic
reactions
Keith et al. (2010)
Lp-PLA2
inhibitor
Restrain formation of LysoPC and oxNEFA Keith et al. (2012), Pabloal and
Juan (2006)
Reduces proinﬂammatory and cytotoxic products Peter et al. (2008)
Scavenger
receptor inhibitor
Inhibits macrophage activation, lipid
metabolism, and inﬂammation
Agnes et al. (2005), Kathryn and
Mason (2006)
Prevent induction of apoptosis, apoptotic cell
clearance, and pathogen recognition
186 P.G. Jamkhande et al.
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level (Toshihiro, 2010). T3 increases levels of both the hepatic
LDL receptor and its mRNA. Thyroid hormone acts on lipid
by increasing the activity of lipoprotein lipase. More recent
understanding of thyroid hormone receptors has led to the
development of thyroid hormone mimetics that have selective
functions and are potential therapeutic agents to lower choles-
terol (Sagar et al., 2012). Current studies have shown that thy-
roid hormone also has direct effects on the blood vessel, which
may attenuate atherogenesis (Toshihiro, 2010).
4.10. Lanosterol synthase inhibitors
Oxido-squalene-cyclase (lanosterol synthase) is the second en-
zyme below the farnesyl pyrophosphate branch point that has
been identiﬁed as a target for novel anticholesterolemic drugs
that could complement statins (Sagar et al., 2012). Lanosterol
synthase is located in the ER and converts 2,3-oxidosqualene-
tolanosterol, the initial four-ringed sterol intermediate in the
cholesterol synthesis pathway. The 24(S), 25-epoxycholesterol
is a ligand of liver X receptor (Andrea et al., 2003). It also sets
the template for the design of inhibitors with improved
pharmacological properties for cholesterol lowering and treat-
ment of atherosclerosis. Lanosterol synthase inhibitors have a
potential to decrease plasma levels LDL and prevents choles-
terol deposition within macrophages (Sagar et al., 2012).
4.11. Cholesterol modifying cytochrome P450
In mammals, excess cholesterol (5-cholestene-3b-ol) is re-
moved mainly through conversion to bile acids, and small por-
tion is used for the production of steroid hormone by the
enzyme called cytochrome P450 (CYP) (Irina, 2006). CYP7A1,
27A1 and 46A1 from the family of P450s are the most impor-
tant enzymes involved in the control of cholesterol levels in the
periphery and brain (Sagar et al., 2012; Irina, 2006). Choles-
terol conversion into bile acids is initiated and controlled by
a liver-speciﬁc enzyme, CYP7A1 that converts cholesterol into
7a-hydroxycholesterol which is the ﬁrst and rate-limiting step
in the classical or neutral bile acid biosynthetic pathway.
Abnormality in the CYP7A1 leads to elevation of total and
LDL cholesterol levels, substantial accumulation of cholesterol
in the liver, and a markedly decreased rate of bile acid excre-
tion (Irina, 2006). CYP7A1 is an important determinant for
reducing plasma cholesterol levels and is considered as a target
for cholesterol lowering.
4.12. AMP-activated protein kinase activator
AMP-activated protein kinase (AMPK), is a heterotrimetric
energy sensing protein, which restores cellular energy balance
by promoting ATP-generating pathways (FA oxidation) and
inhibiting ATP-utilizing pathways (FA synthesis) (Sagar
et al., 2012). Different physiological processes like conditions
that lead to alterations of the intracellular AMP/ATP ratio
(e.g., hypoxia, glucose deprivation), calcium concentration
and action of various hormones, cytokines, and adipokines
stimulate AMPK. AMPK phosphorylates and inactivates acet-
yl-CoA carboxylase 1 and 3-hydroxy-3-methylglutarylCoA
reductase thereby inhibiting synthesis of new FA and choles-
terol whereas phosphorylation of acetyl-CoA carboxylase 2by AMPK causes an increase of FA oxidation (Bei et al.,
2009). Also AMPK system plays a major role in regulating glu-
cose and lipid metabolism by effect on energy metabolism and
long-term effect on gene expression in the liver. In liver, activa-
tion of AMPK results in decreased production of plasma TG
and cholesterol and enhanced FA oxidation that could be used
for inhibition de novo hepatic lipogenesis (Sagar et al., 2012).
4.13. Omega-3 FAs
Omega-3 belongs to the polyunsaturated FA family, which in-
cludes the 20-carbon eicosapentanoic acid and 22-carbon
docosahexaenoic acid, having an ability to reduce the TG lev-
els and atherogenic remnant lipoproteins (Vasilios et al., 2011).
These FAs mainly present in marine sources, especially sal-
mon, mackerel, sardines, tuna and at 4 g/day were found to
be effective in lowering TG concentration, particularly in the
postprandial state (Sagar et al., 2012). Combination of statins
and Omega-3 FAs signiﬁcantly decreases TG, VLDL, and
non-HDL-c levels compared with simvastatin alone (Vasilios
et al., 2011). Synthesis of FAs involves an expression of
SREBP-1 which is inhibited by Omega-3 FA. Omega-3 FAs
also show hypotriglyceridemia, anti-aggregatory, anti-inﬂam-
matory, and anti-arrhythmatic responses (Sagar et al., 2012).
4.14. Heat shock protein-65 and CETP vaccine
Atherosclerosis is inﬂammation mediated disease characterized
by the accumulation of lipids and ﬁbrous elements in the arter-
ies. Anti-inﬂammatory or lipid-lowering treatments could be
useful for alleviating morbidity and mortality of atheroscle-
rotic cardiovascular diseases. However, a vaccine designed to
target inﬂammation and lipid simultaneously is found to be
more useful for the management of atherosclerosis. Study by
Long Jun et al. showed that, a vaccine designed to target heat
shock protein-65 and CETP, reduces TC and LDL and size of
atherosclerotic plaques. Long term nasal administration of
heat shock protein 65 also helps to reduce atherosclerosis
through the reduction of immune tolerance against self-antigen
and down-regulation of atherosclerotic inﬂammation (Long
et al., 2012).
4.15. Nitric oxide
Hypercholesterolemia and atherosclerosis disturb the endothe-
lium-dependent nitric oxide (NO) mediated regulation of the
vascular tone and endothelial dysfunction is an early event in
atherogenesis and coronary heart disease (Claudio and Louis,
2001). NO synthase (NOS) synthesizes NO which is a crucial
modulator of vascular disease. The protective role of NO is be-
cause of its ability to suppress abnormal proliferation of vascu-
lar smooth muscle cells. NO is also involved in various
intracellular effects that lead to vasorelaxation, inhibition of
leukocyte chemotaxis, endothelial regeneration, and platelet
adhesion. Endothelial damage in atherosclerosis reduces bioac-
tivity of endothelial NO synthase that subsequent reduces syn-
thesis of NO and stimulates degradation of NO by generating
reactive oxygen species (Claudio et al., 2006). Several mecha-
nisms like lipoprotein-induced alterations in signal transduc-
tion, increases in superoxide anion generation followed by
degradation of NO, reduced afﬁnity of NOS for L-arginine,
188 P.G. Jamkhande et al.and/or elevated levels of circulating antagonists enhances
derangement of the NOS pathway (Claudio and Louis, 2001;
Russo et al., 2002). Various vasculoprotective agents act
through increasing NO synthesis. L-Arginine, the precursor
of NO, can be used for the management of atherosclerosis
and atherosclerotic coronary diseases (Claudio et al., 2006).
4.16. Phospholipase A2 inhibiter
Several types of phospholipases are associated with atheroscle-
rosis and its complications. The body contains ﬁve different
types of phospholipase A2(PLA2), secreted phospholipaseA2
(sPLA2), cytosolic phospholipase A2 (cPLA2), calcium-inde-
pendent PLA2s, lysosomal PLA2s (Lp-PLA2) and platelet-acti-
vating factor acetylhydrolases (Keith, 2010). These are
involved in the formation of pro-inﬂammatory products and
hence may have signiﬁcant effects on atherogenesis.
4.16.1. sPLA2 inhibiter
This form of PLA2 is associated with a range of inﬂammatory,
autoimmune and allergic disorders with different isoforms
being expressed and released by speciﬁc inﬂammatory cells.
In addition to hydrolytic activity, it also interacts with high
afﬁnity receptors on inﬂammatory cells or with cell-surface
proteoglycans, for example inducing degranulation in mast
cells, neutrophils and eosinophils and activating endocytosis
in macrophages. sPLA2s is involved in promotion of chemo-
kine production from monocytes and macrophages and mod-
iﬁcation of plasma lipoproteins, making them more
atherogenic. sPLA2s active on circulating lipoproteins exhibits
a different effect from those located in the plaque. sPLA2-V is
associated with plaque smooth muscle cells and surrounding
foam cell which is active on lipoproteins in human serum.
sPLA2-X has the highest catalytic activity toward phosphati-
dylcholine and is present in human lesion. It is observed that
LDL concentrations in patients are reduced when a non-selec-
tive sPLA2 inhibitor is administered hence, when the overall
sPLA activity is inhibited it may lead to reduced clearance of
LDL (Keith, 2010).
4.16.2. Lp-PLA2 inhibiter
Lipoprotein-associated PLA2 is an enzyme produced by
inﬂammatory cells, which binds to apolipoprotein B-contain-
ing lipoproteins and degrades oxidatively modiﬁed phospho-
lipids in low-density lipoprotein cholesterol particles, leading
to formation of pro-inﬂammatory and cytotoxic products.
Approximately 80% of Lp-PLA2 circulates bound to LDL
cholesterol, speciﬁcally to apolipoprotein B-100, and remain-
ing bound to high-density lipoprotein and remnant lipoprotein
particles. It is associated with small, dense and electronegative
LDL particles that are believed to be more proatherogenic.
Lp-LPA2 acts mainly on oxidized LDL. Oxidative
modiﬁcation of polyunsaturated FAs in the sn-2 position of
phospholipids within LDL molecules render them susceptible
to hydrolysis by Lp-PLA2, resulting in the formation of
lysophosphatidylcholine and oxidized nonesteriﬁed FAs,
pro-inﬂammatory and cytotoxic products respectively. Lyso-
phosphatidylcholine and oxidized nonesteriﬁed FAs further
stimulate expression of adhesion molecules and cytokines by
endothelial cells, plaque-based macrophages and other leuko-
cytes. Lp-PLA2 is strongly expressed in the necrotic core ofcoronary lesions and in the surrounding macrophages of
vulnerable and ruptured plaques, which is consistent with the
proposed mechanism. Inhibitors of this enzyme can be used
for the management of atherosclerosis and high-risk coronary
artery disease patient (Eva, 2010).
4.17. Scavenger receptor
The uptake of modiﬁed LDL is promoted by scavenger recep-
tors that promote the cellular accumulation of cholesterol.
Macrophages in lesions have been shown to express more than
six structurally different scavenger receptors. These scavenger
receptors involved in initiation of signaling cascades regulate
activation of macrophage, lipid metabolism, and inﬂammatory
processes that may control the development and stability of
the atherosclerotic plaque. These receptors also regulate induc-
tion of apoptosis, apoptotic cell clearance, and pathogen rec-
ognition that may differentially impact early and more
complex lesions. Inhibition of these scavenger receptor path-
ways may lead to inhibition of various pro-inﬂammatory
events which contribute in progression of atherosclerosis
(Kathryn and Mason, 2006; Agnes et al., 2005).
All the drug targets and their possible mechanisms of action
for the management of atherosclerosis are summarized in
Table 1.
5. Conclusion
Atherosclerosis is a metabolic disorder characterized by
hyperlipidemia and chronic inﬂammation. Although nowa-
days many therapies like HMG CoA reductase inhibitors,
bile acid sequestrants, ﬁbrates, niacin are successfully impli-
cated to treat altered lipid proﬁle associated with atheroscle-
rosis and atherosclerotic coronary disorders, still it lacks in a
signiﬁcant increase in the beneﬁt-to-risk ratio. Hence, the
present review mainly gives the idea about the recent recep-
tor and signaling pathways that take part in the starting
stage of atherosclerosis formation that is from the plaques
form to the fatty streak formation. PPARs are regulators
of several metabolic pathways; hence agonists of these recep-
tors can be used as therapeutics of dyslipidemia. Inhibition
of CETP elevates plasma HDL cholesterol and reduces plas-
ma LDL cholesterol. Squalene synthase and lanosterol syn-
thase are the enzymes involved in cholesterol synthesis;
their inhibitors will be the possible target for the reduction
of hyperlipidemia. The inhibitors of ACAT, DGAT, MTTP
and PLA2 are also used as targets for hyperlipidemia associ-
ated atherosclerotic diseases. Lipid lowering effect of thyroid
hormone analogue will be a possible mechanism to altered
lipid proﬁle. Cholesterol modifying CYP P450, AMPK acti-
vators, and omega-3 FAs, heat shock proteins-65, will be the
new therapeutic drug targets in the management of
atherosclerosis.
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